To determine if systemic treatment with IL-2-REH could provide therapeutic benefit during an ongoing immune response, we used the DSS-induced colitis model, treating mice with IL-2, IL-2-REH, or the previously described IL-2Rα selective IL-2 mutein, IL-2-N88D (Peterson et al., 2018), starting on day 3 at the onset of DSS-induced weight loss (Figure 6A). Here, IL2 is linked to colitis.